EUVIMEDEUVIMED entdecken
Crossref

Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice

Soichiro Ide, Naotaka Izuo, Yuiko Ikekubo, George R Uhl, Ichiro Sora, Atsumi Nitta, Kazutaka Ikeda

Life Sciences · 2026

DOI: 10.1016/j.lfs.2025.124116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026. Verfasst von Soichiro Ide und 6 weiteren Autor:innen. Beteiligte Einrichtung: Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. Electronic add…. Hauptthemen laut MEDLINE: Adrenergic alpha-Antagonists, Excitatory Amino Acid Antagonists, Nicotine, Behavior, Addictive. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Tokyo Medical and Dental University, Smoking Research Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nicotine addiction remains a global public health problem, with high relapse rates and limited long-term success from current treatments. This highlights the need for new therapeutic strategies that target novel mechanisms of nicotine addiction. Ifenprodil, a GluN2B-containing N-methyl-d-aspartate receptor antagonist and G protein-activated inwardly rectifying potassium inhibitor, among other actions, potentially offers a new approach. The present study investigated the efficacy of ifenprodil in reducing nicotine-induced addiction-like behaviors. We evaluated effects of systemic ifenprodil administration on nicotine-induced behaviors in mice using two experimental paradigms: a lateral hypothalamus intracranial self-stimulation (lhICSS) test using a rate-frequency procedure and a two-bottle choice preference test. Dopamine transporter (DAT) knockout (KO) and wild-type mice were used to investigate nicotine's effects on reward-related behavior. Nicotine and ifenprodil were delivered via intraperitoneal injection. In wild-type mice, acute nicotine (0.1-1.0 mg/kg) had no significant effect on lhICSS rates across stimulation frequencies, although a low dose (0.1 mg/kg) produced a modest increase. The 0.1 mg/kg dose of nicotine but not higher doses (0.3 or 1.0 mg/kg) significantly enhanced lhICSS rates in DAT-KO mice. Pretreatment with ifenprodil (1-10 mg/kg) dose-dependently reduced the nicotine-induced enhancement of reward in DAT-KO mice. In wild-type males, ifenprodil acutely decreased nicotine preference in the two-bottle choice test following chronic nicotine exposure. These findings indicate that ifenprodil suppresses nicotine-related behaviors primarily in mice on a hyperdopaminergic (DAT-KO) background. Although further validation in wild-type models is warranted to clarify the translational generalizability of these findings, ifenprodil may be a novel approach for the treatment of nicotine addiction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic alpha-AntagonistsExcitatory Amino Acid AntagonistsNicotineBehavior, AddictiveMaleFemaleAnimalsMiceMice, Inbred C57BLMice, KnockoutTobacco Use DisorderDopamine Plasma Membrane Transport ProteinsSelf StimulationPiperidines

Stichwörter der Autor:innen

Dopamine transporter knockout mouseICSSIfenprodilNicotine addiction

Substanzen

ifenprodilAdrenergic alpha-AntagonistsExcitatory Amino Acid AntagonistsNicotineDopamine Plasma Membrane Transport ProteinsPiperidines

Autor:innen und Institutionen

  • Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. Electronic address: ide-si@igakuken.or.jp.
  • Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan; Research Center for Advanced Science and Technology, The Univ…
  • Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.
  • Departments of Neurology and Pharmacology, University of Maryland School of Medicine, and VA Maryland Healthcare System, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
  • Department of Digital Psychiatry, Kobe University Graduate School of Medicine, Kobe Biotechnology Center, 1-5-6 Minatojima Minamimachi, Chuo Ward, Kobe, 650-0047, Japan.
  • Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.

Förderung

  • Tokyo Medical and Dental University
  • Smoking Research Foundation
  • Japan Society for the Promotion of Science
  • Tamura Science and Technology Foundation

Zitieren

APA

Ide, S., Izuo, N., Ikekubo, Y., Uhl, G. R., Sora, I., Nitta, A., & Ikeda, K. (2026). Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice. Life Sciences. https://doi.org/10.1016/j.lfs.2025.124116

Vancouver

Ide S, Izuo N, Ikekubo Y, Uhl GR, Sora I, Nitta A, et al. Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice. Life Sciences. 2026. doi:10.1016/j.lfs.2025.124116

BibTeX
@article{Ide2026,
  author = {Ide, Soichiro and Izuo, Naotaka and Ikekubo, Yuiko and Uhl, George R and Sora, Ichiro and Nitta, Atsumi and Ikeda, Kazutaka},
  title = {Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice},
  journal = {Life Sciences},
  year = {2026},
  doi = {10.1016/j.lfs.2025.124116}
}
Kostenlos starten →